Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527819) titled 'Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)' on April 7.

Study Type: Observational

Primary Sponsor: Peter MacCallum Cancer Centre, Australia

Condition: Triple Negative Breast Cancer (TNBC)

Recruitment Status: Not recruiting

Date of First Enrollment: April 8, 2026

Target Sample Size: 75

Countries of Recruitment: Australia

To know more, visit https://clinicaltrials.gov/study/NCT07527819

Disclaimer: Curated by HT Syndication....